NEW DELHI - India's Supreme Court rejected Monday a patent bid by Swiss drug giant Novartis in a landmark ruling activists say will allow continued supply of cheap generic drugs and save lives in poorer nations.
Indian protesters lift a balloon shaped like a pill during a demonstration against the Swiss drug manufacturer Novartis, in Mumbai on December 21, 2012. India's Supreme Court has rejected a patent bid by Swiss drug giant Novartis in a landmark ruling that activists say will protect cheap generic drugs and save lives in developing nations.
Novartis fought a seven-year legal battle to gain patent protection for an updated version of its blockbuster leukaemia drug Glivec, arguing the compound was a significant improvement because it is more easily absorbed by the body.
This article is older than 60 days, which we reserve for our premium members only.You can subscribe to our premium member subscription, here.